As of Jun 22, 2026, SYK's PEG ratio of 2.11 reflects its valuation relative to its growth rate. This result reflects a P/E ratio of 34.86 measured against EPS growth of 16.5%.
Stryker's ten years historical PEG ratio averages out to 2.3. Compared to historical data, SYK's 2.11 PEG ratio represents a decrease of 8%. SYK hit its maximum PEG ratio of 8.36 during the Sep 2023 quarter over the last ten years. The Dec 2018 quarter marked the lowest reading at 0.07, indicating the most attractive growth-adjusted valuation.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 5.18 | 41.4 | 8% |
| 2024 | N/A | 45.81 | -5.8% |
| 2023 | 1.06 | 35.91 | 33.9% |
| 2022 | 2.2 | 39.24 | 17.8% |
| 2021 | 2.09 | 50.55 | 24.2% |
| 2020 | N/A | 57.52 | -23.5% |
| 2019 | N/A | 37.69 | -41.4% |
| 2018 | 0.07 | 16.5 | 248% |
| 2017 | N/A | 56.72 | -38% |
| 2016 | 1.79 | 27.23 | 15.2% |
| 2015 | 0.13 | 24.33 | 180.9% |
| 2014 | N/A | 69.36 | -48.9% |
| 2013 | N/A | 28.25 | -22% |
| 2012 | N/A | 16.08 | -2% |
| 2011 | 1.7 | 14.28 | 8.4% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 2.28 | 37.6 | 16.5% |
| Dec 2025 | 5.18 | 41.4 | 8% |
| Sep 2025 | N/A | 47.88 | -18.1% |
| Jun 2025 | N/A | 51.72 | -15.7% |
| Mar 2025 | N/A | 49.63 | -15.3% |
| Dec 2024 | N/A | 45.81 | -5.8% |
| Sep 2024 | 1 | 38.31 | 38.5% |
| Jun 2024 | 1.39 | 37.51 | 26.9% |
| Mar 2024 | 1.46 | 40.44 | 27.7% |
| Dec 2023 | 1.06 | 35.91 | 33.9% |
| Sep 2023 | 8.36 | 40.13 | 4.8% |
| Jun 2023 | 1.43 | 42.67 | 29.8% |
| Mar 2023 | 1.4 | 41.19 | 29.5% |
| Dec 2022 | 2.2 | 39.24 | 17.8% |
| Sep 2022 | 1.09 | 31.16 | 28.7% |
Measured against past performance, SYK's PEG ratio comes in under the 3, 5 and 10-year averages.
With a PEG of 2.11, SYK ranks higher than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 0.55, Stryker's PEG is 284% higher.
Among its peers, SYK has a PEG ratio below stock MDT, while higher than BSX's and GMED's.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| GMED Globus Medical Inc | 0.08 | $10.75B |
| BSX Boston Scientific Corp | 0.25 | $65.89B |
| SYK Stryker Corp | 2.11 | $116.81B |
| MDT Medtronic plc | 6.41 | $101.47B |
| EW Edwards Lifesciences Corp | N/A | $49.45B |
| BAX Baxter International Inc | N/A | $10.15B |
| IART Integra Lifesciences Holdings Corp | N/A | $1.37B |
| WAT Waters Corp | N/A | $35.18B |
| CNMD CONMED Corp | N/A | $979.75M |
| JNJ Johnson & Johnson | N/A | $556.77B |
SYK's Jun 22, 2026 PEG ratio comes in at 2.11.
Historical data over a 3-year period puts SYK's average PEG ratio at 2.77.
Historical data over a 5-year period puts SYK's average PEG ratio at 2.58.
In the last ten years, SYK's peak PEG ratio of 8.36 occurred in the Sep 2023 quarter.
At present, SYK's PEG ratio runs 8% lower than its 10-year historical average.
Slow earnings growth combined with a rich valuation drives SYK's PEG ratio to 2.11.
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jun 22, 2026, Stryker carries a PE ratio of 34.86. Earnings grew at 16.5% over the TTM period ending Mar 2026. Applying the formula, this yields a PEG ratio of 2.11. PEG RATIO(2.11) = PE RATIO(34.86) / EPS GROWTH(16.5%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.